Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
-INCLUSION CRITERIA:~1. Healthy women and men who are greater than or equal to 18 and less than or equal to 50 years of age.~2. Willingness to complete all study visits and comply with all study requirements.~3. A male subject is eligible for the study if he agrees to practicing abstinence or using a condom with spermicide plus an acceptable form of contraception (see inclusion criteria 4) being used by any female partner from 4 weeks before study start to 12 weeks after the second vaccine administration.~4. A female participant is eligible for this study if she is not pregnant or breast feeding and 1 of the following:~   * Of non-child bearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year).~  * Of childbearing potential but agrees to practice effective contraception or abstinence for 4 weeks prior to study initiation through 12 weeks after the second vaccine administration. Acceptable methods of contraception include a male partner who is sterile and is the sole sexual partner of the female participant or a male partner who uses a condom with spermicide plus 1 or more of the following: 1) implants of levonorgestrel; 2) injectable progestogen; 3) an intrauterine device with a documented failure rate of \<1%; 4) oral contraceptives; and 5) double barrier method including diaphragm.~5. Willing to have samples stored for future research (including genetic research).~6. Agrees to abstain from alcohol intake for 24 hours prior to each study visit.~7. Agrees to not donate blood or blood products throughout the study.~EXCLUSION CRITERIA:~1. Participant has any underlying or current medical condition, which, in the opinion of the Investigator, would interfere with the participation in the study.~2. Individual with body mass index (BMI) less than or equal to 18 and greater than or equal to 40.~3. Participants who have a clinically significant (as determined by the PI) baseline Grade 1 or greater toxicity, or any Grade 3 or greater toxicity (regardless of clinical significance) by the toxicity table.~4. Receipt of blood or blood products (including immunoglobulins) within 3 months prior to enrollment.~5. Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is greater) prior to enrollment.~6. Receipt of any unlicensed vaccine within 6 months prior to enrollment.~7. Self-reported or known history of alcoholism or drug abuse within 6 months prior to enrollment, or positive urine/serum test for drugs of abuse at screening~8. Self-reported or known history of psychiatric or psychological issues that require treatment and are deemed by the PI to be a contraindication to protocol participation.~9. History of a previous severe allergic reaction with generalized urticaria, angioedema, anaphylaxis or anaphylactoid reaction.~10. Any condition or event that, in the judgment of the PI, is a contraindication to protocol participation or impairs the volunteer's ability to give informed consent.~11. Has a known allergy to any of the components of the vaccine.~12. Has a history of severe immunization reaction.~13. Has a severe allergic reaction to mosquito bites

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- AGS-v (Type: EXPERIMENTAL): AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
- AGS-v with adjuvant (Type: EXPERIMENTAL): ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL)on Day 0 and on Day 21
- Placebo (Type: PLACEBO_COMPARATOR): WFI (0.5mL) on Day 0 and Day 21

Based on this trial design, predict the completion outcome and termination type (if applicable).